Standout Papers

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer p... 2010 2026 2015 2020 2.3k
  1. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial (2010)
    Johann S. de Bono, Stéphane Oudard et al. The Lancet

Immediate Impact

3 by Nobel laureates 15 from Science/Nature 74 standout
Sub-graph 1 of 20

Citing Papers

Androgen receptor activity in T cells limits checkpoint blockade efficacy
2022 StandoutNature
Ferroptosis Inducers Are a Novel Therapeutic Approach for Advanced Prostate Cancer
2021 Standout
1 intermediate paper

Works of Martin Roessner being referenced

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
2010 Standout

Author Peers

Author Last Decade Papers Cites
Martin Roessner 2190 156 103 948 887 11 2.8k
Daniel Petrylak 1880 54 9 804 716 8 2.3k
Liji Shen 2728 138 61 1240 1099 35 3.4k
Youn C. Park 2635 125 42 762 754 20 3.0k
Bryan Selby 3215 119 56 905 1106 10 3.6k
Ivo Kocák 2416 93 48 1363 926 40 3.2k
J Horti 3561 141 57 1592 1155 17 4.5k
William R. Berry 3834 152 59 1755 1244 22 4.8k
Mary Ellen Taplin 4080 178 101 1528 950 27 5.0k
Stephen D. Rubin 1312 53 76 2583 791 17 3.9k
Luis Fein 2530 124 68 1612 707 52 3.7k

All Works

Loading papers...

Rankless by CCL
2026